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Mycobacterial Pulmonary Infections in Patients with Idiopathic 
Pulmonary Fibrosis
Patients with idiopathic pulmonary fibrosis (IPF) have an increased risk for developing 
tuberculosis (TB). However, no studies have been reported regarding the development of 
nontuberculous mycobacterium (NTM) lung disease (NTMLD). We reviewed 795 patients 
with IPF from five university hospitals who were diagnosed by histological or radio-clinical 
criteria. In the 795 patients with IPF, pulmonary infections with mycobacterium 
tuberculosis (MTB) and NTM were found in 35 (4.4%) and 16 patients (2.0%), respectively, 
which was a higher frequency than that found in the general population. TB was more 
common in patients treated with immunosuppressants than in those who did not receive 
immunosuppressants (2.6% vs 1.4%, P = 0.12). Among the IPF patients who had 
mycobacterial infections,immunosuppressant users developed TB or NTMLD within 1 yr 
after treatment with immunosuppressants ,while those occurred later than 2 yr after 
diagnosis of IPF in the subjects that did not receive immunosuppressants. Among 51 IPF 
patients who had mycobacterial infections, 9 (18%) died during follow-up. Of these, three 
died due to progression of pulmonary tuberculosis. TB and NTMLD is relatively common in 
patients with IPF in Korea and may be fatal in some groups. Careful evaluation of TB and 
NTMLD is necessary not only for immunosuppressant users, but also for nonusers with IPF.
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Idiopathic pulmonary fibrosis (IPF) is a progressively deterio-
rating lung disease of unknown etiology, characterized by fibro-
blast proliferation and extracellular matrix consolidation (1). 
Globally, the incidence of IPF has been increasing, probably due 
to environmental factors, an increase in the elderly population, 
and early diagnosis using high-resolution computed tomogra-
phy (HRCT) (2, 3). IPF is often lethal for specific patient popula-
tions with a median survival of approximately 3 yr (4-7). In ad-
dition, pulmonary infections caused by various organisms can 
often exasperate IPF, causing a high mortality rate even among 
the general patient population (8-10). Therefore, infection at 
initial presentation or during follow-up alters the required ther-
apeutic intervention and influences patient prognosis and du-
ration of survival, especially within Asian countries (8-11).
 Mycobacterium tuberculosis (MTB) is a relatively common 
cause of chronic lung infections worldwide (12). Recently, the 
prevalence of nontuberculous mycobacteria (NTM) infection 
has increased rapidly in developing countries, including Korea 
(13-16). In studies conducted in the 1970-90s that examined pa-
tients with idiopathic chronic interstitial lung disease, the posi-
tive culture rate for MTB was 5%-6.2% (17, 18). This incidence 
was 4-5 times higher than that of the general population in the 
same country at the same time. This indicates that IPF might 
establish pulmonary susceptibility to mycobacterial infection. 
In the case of IPF patients with NTM infection, little data are avail-
able in the literature. For example, one of the few findings that 
were reported is the high rate of M. fortuitum found in NTM in-
fections among patients with underlying IPF (19). However, 
more comprehensive analysis of other types of NTM infections 
is needed for proper use of immunosuppressants in IPF. This is 
because the current treatment guidelines for IPF recommend 
steroid and immunosuppressive drugs as the main therapy (1, 
20), which are expected to increase the chance of reactivation 
of dormant pulmonary infections and mortality caused by TB 
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and nontuberculous mycobacterium lung disease (NTMLD). 
 However, to the best of our knowledge, no data exist on the 
prevalence or clinical manifestations of NTM infection in pa-
tients with IPF. Therefore, this study investigated the prevalence 
of TB and NTMLD in patients with IPF at the initial presentation 
and during follow-up, and evaluated the clinical courses of TB 




In total, 795 patients with IPF were diagnosed using the criteria 
of the American Thoracic Society and the European Respiratory 
Society (20), with compatible findings on surgical lung biopsy 
(n = 486; 68.5%) or using radio-clinical criteria (n = 309; 31.5%) 
at 5 university hospitals including Soonchunhyang University 
Bucheon Hospital, Soonchunhyang University Seoul Hospital, 
University of Ulsan Asan Medical Center, Yonsei University Sev-
erance Hospital and Inha University Hospital in Korea from 1992 
to 2007.
 Interstitial lung diseases with known etiologies, such as col-
lagen vascular disease (CVD), a history of drug use, or environ-
mental exposure, were excluded. At the initial evaluation of IPF, 
all of the subjects underwent sputum examination for acid-fast 
bacilli (AFB) stain and culture for Mycobacterium. Bronchoalve-
olar lavage (BAL) was performed in eligible subjects. During the 
follow-up period, sputum was examined for AFB smear and cul-
ture when pulmonary infection was suspected, based on clini-
cal manifestation or on the radiologic evaluation, including chest 
radiograph (posteroanterior view) or high-resolution comput-
ed tomography (HRCT). HRCT was performed in all patients at 
the time of IPF diagnosis, as well as at the time when pulmonary 
infection with MTB or NTM was suspected. NTMLD was diag-
nosed using the American Thoracic Society/Infectious Diseases 
Society of America consensus, based on clinical pulmonary symp-
toms and radiologic and microbiologic findings (15). Briefly, 
NTMLD was diagnosed when symptomatic patients exhibited 
newly developed multifocal bronchiectasis, cavitation, consoli-
dation, or nodules as well as one of the following three microbi-
ologic criteria: 1) at least two positive cultures from sputum; 2) 
one positive culture from a bronchial wash or lavage; or 3) a trans-
bronchial lung biopsy that resulted in a diagnosis of NTM or a 
biopsy exhibiting mycobacterial histopathologic features and 
one or more positive sputum or bronchial wash. Patients were 
treated as recommended by the guidelines of the World Health 
Organization (21) and a successful cure of TB or NTMLD was 
defined by two separate negative sputum cultures during the 
last month of treatment (22). 
 
Statistical analyses
Statistical analyses were performed using the SPSS software (ver. 
14.0 for Windows). Differences in variables between groups were 
determined using Student’s t-test. The development of pulmo-
nary TB or NTMLD between immunosuppressant users and 
nonusers in the IPF cohort was compared using the chi-square 
test. Data are expressed as the mean ± SE. P values < 0.05 were 
deemed to indicate statistical significance.
Ethics statement
This study was approved by the institutional review board of 
Soonchunhyang University Bucheon Hospital (IRB No. SCHBC_
IRB_2011-58). Written informed consent was obtained from all 
patients.
RESULTS
Prevalence and demographic characteristics of TB and 
NTMLD in patients with IPF 
Among the 795 patients with IPF, 35 (4.4%) and 16 (2.0%) were 
diagnosed as having pulmonary infections with MTB and NTM, 
respectively. The sample sources of AFB were sputum (n = 41; 
82%), bronchial wash or lavage (n = 5; 10%), and lung tissue 
(n = 4; 8%) (Table 1). Of the demographic features, age at IPF 
diagnosis was significantly older in the NTMLD group than in 
the TB group or for all subjects (71.0 ± 1.8 vs 62.6 ± 1.5 or 63.9 ±  
0.4 yr; P = 0.006 and P = 0.005, respectively). A tendency toward 
a higher proportion of males was observed in the NTMLD and 
TB groups compared to all patients, although the difference was 
marginal (P = 0.057). The proportions of smokers and duration 
of IPF were similar between the two groups (Table 1).
 Among 35 patients with TB, 18 (51.4%) were diagnosed at the 
initial presentation of IPF and 17 developed TB during the follow-
up (Table 2). A total of 16 patients were diagnosed with NTMLD: 
11 (68.7%) at the initial presentation and 5 during follow-up. 
M. avium complex (n = 14; 88%) was the most common type of 
NTM, followed by M. abscessus (n = 1; 6%) and M. szulgai (n = 1; 
6%). Of the 795 patients with IPF, 499 had been treated with im-
Table 1. Clinical characteristics of the patients with TB or NTMLD among the 795 
subjects with IPF
Parameters Total subjects TB NTMLD 
Numbers (proportion) 795 35 (4.4%) 16 (2.0%) 
Sex (M/F)  549/246 28/7 14/2 
Age (yr) 63.9 ± 0.4 62.6 ± 1.5 71.0 ± 1.8*
Smoking (CS:ES:NS) 138/396/261 8/19/8 2/10/4
Sources for TB/NTMLD diagnosis 
   Sputum (n) 
   BALF (n) 









795 IPF patients were diagnosed using the criteria of the American Thoracic Society 
and the European Respiratory Society (20), with compatible findings on surgical lung 
biopsy (n = 486) or using radio-clinical criteria (n = 309). *P = 0.006 and 0.005 vs 
MTB and total subjects respectively. TB, tuberculosis; NTMLD, nontuberculous myco-
bacterium lung disease; IPF, idiopathic pulmonary fibrosis; CS, current smoker; ES, 
ex-smoker; NS, never smoker; BALF, bronchoalveolar lavage fluid.
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munosuppressants, while 296 had symptomatic treatment only 
(Table 2). A total of 16 of the 499 immunosuppressant users (3.2%) 
developed TB or NTMLD, compared to 6 of 296 (2.0%) in the 
symptomatic treatment group; 13 of the 499 patients on immu-
nosuppressant therapy developed active TB compared to 4 of 
the 296 patients receiving symptomatic therapy (2.6% vs 1.4%, 
P = 0.12). Of five patients with newly developed NTMLD, three 
were being treated with immunosuppressants (0.6%) and two 
were receiving symptomatic therapy only (0.7%). Among the 
immunosuppressant users, the interval between the date of TB 
or NTMLD diagnosis and the initiation of immunosuppressant 
therapy was 5.8 ± 2.6 and 8.3 ± 0.2 months, respectively. 
Clinical course of NTMLD and pulmonary TB in patients 
with IPF
The majority of new TB (76%, 13 of 17 subjects) and NTMLD 
(60%, 3 of 5 subjects) developed during the treatment with im-
munosuppressants. All patients discontinued prednisone or 
azathioprine after the diagnosis of mycobacterial infection and 
were treated with anti-MTB or -NTM chemotherapy according 
to the guidelines of the American Thoracic Society and the World 
Health Organization (21, 22). Regarding the treatment response 
and clinical course of TB and NTMLD, 22 (63%) of 35 patients 
with TB and 9 (56%) of 16 patients with NTMLD were cured 
(Table 3). Six and three patients in the two groups died during 
the anti-MTB or -NTMLD treatments, respectively. The causes 
of death were acute exacerbation of IPF, hemoptysis, and pro-
gression of TB (Table 3). The overall mortality rate during treat-
ment of mycobacterial lung infection was 17.6% (9/51).
 
DISCUSSION 
The present study showed that there was a higher prevalence of 
pulmonary TB and NTMLD in patients with IPF (4.4% and 2.0%, 
respectively). Because the prevalence of tuberculosis is 1% in 
the general Korean population (23), these data indicate that the 
incidence of tuberculosis in patients with IPF is more than four 
times higher than that of the general population. NTM infec-
tions, which were once regarded as contamination or coloniza-
tion from the environment, are now known to be potential patho-
gens in certain patients. The prevalence of NTMLD has not been 
well documented. In industrialized countries, incidence rates 
vary from 1.0 to 1.8 cases per 100,000 (24). The rate of NTM lung 
disease is higher in immunocompromised hosts, such as those 
with HIV infection, diabetes, and organ transplant recipients 
(25-27). Furthermore, advances in diagnostic technology have 
facilitated the detection and identification of NTM (15). How-
ever, to date, no comprehensive data exist on NTM infections in 
patients with IPF. In the present study, the prevalence of NTMLD 
in patients with IPF was 2.0%, which we presumed to be a very 
high rate compared to the general population. 
 Structurally damaging lung diseases, such as chronic obstruc-
tive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, 
and pneumoconiosis, increase susceptibility to NTMLD (15, 28-
30). This can be explained by mechanical factors and impaired 
local host immunity. In vitro experiments have revealed that 
NTM is only able to adhere to damaged, not intact, mucosa (31). 
Impaired local immunity involves impaired clearance of secre-
tions, abnormal airway surface liquids, and persistent airway 
inflammation (32). The pathology of IPF is primarily character-
ized by interstitial fibrosis, inflammation, and fibroblastic foci. 
In the later stages, secondary structural damage, such as paren-
chymal cystic change, traction bronchiectasis, and honeycomb 
change, develops. These structural (mechanical) changes can 
be attributed to impairment of local immunity leading to a more 
susceptible environment to MTB or NTM as demonstrated in 
the present study. 
 The prevalence of TB in patients with IPF (4.3%) is slightly 
lower in the present study than the prevalence reported by Chung 
et al. (6.2%) in Korea (18). They observed histologically (n = 2) 
or bacteriologically (n = 7) confirmed pulmonary tuberculosis 
among 143 patients with IPF. Although another single-center 
study reported that M. fortuitium were frequently isolated from 
underlying lung disease including prior tuberculosis, lung can-
cer or IPF (19), we did not identify M. fortuitum in the present 






   Time of mycobacterial infection 
   at first visit
   during the follow-up
795 35 (4.4%)
  18 (51.4%)
  17 (48.6%)
16 (2.0%)
  11 (68.7%)
    5 (31.3%)
Subjects without immunosuppressants (No.) 296   4 (1.4%)   2 (0.7%)
Time of infection after IPF diagnosis, 
   months (range) 
43.75± 10.9 
(26-75) 
38.5 ± 6.5 
(32-45) 
Subject with immunosuppressants (No.)
   PDL 
   Azathioprine + PDL 
499  13 (2.6%)†
  3
10
   3 (0.6%)†
1
2
Time of infection after immunosuppressants, 
   months (range)‡
5.8 ± 2.6 
(2.5-10.5) 
5.8 ± 2.6 
(2.5-10.5) 
* Identification of sixteen NTMLD showed M. avium complex (n = 14, 88%) and M. 
abscessus (n = 1, 6%) and M. szulgai (n = 1, 6%); †indicates the subjects whose 
mycobacterial infection occurred during treatment with immunosuppressants; ‡indi-
cates the duration that mycobacterial infection occurred after start of immunosuppres-
sants. PDL, prednisone.
Table 3. Clinical course of MTB and NTMLD in the IPF cohorts
Clinical course MTB (n = 35) NTM (n = 16) 
Cured 22 9
Expired   6 3
Cause of death
   Acute exacerbation
   Hemoptysis
   Progression of mycobacterial infection
   Follow-up loss during the treatment











Park S-W, et al. • Mycobacterial Infections in Pulmonary Fibrosis
http://jkms.org  899http://dx.doi.org/10.3346/jkms.2012.27.8.896
study. The difference between these studies may be due to dif-
ferent numbers of patients or single-center versus multicenter 
designs. 
 In patients with IPF, about half (51%) of the TB cases were 
found at the time of initial diagnosis of IPF and the remaining 
half developed new TB during the follow-up period. In the case 
of NTMLD, 69% of NTMLD cases were found at the initial visit 
for the diagnosis of IPF. These high diagnosis rates at initial eval-
uation may be explained by the fact that prevalence of TB is still 
high especially elderly in Korea. Regarding NTMLD, most of our 
patients (14 of 16) have bronchiectasis or cavity due to previous 
TB. These lung structure changes enable more easily infect to 
NTM in addition to IPF. These data indicate that pulmonary TB 
and NTMLD should be suspected when respiratory symptoms 
or chest radiographs change during the follow-up.  
 More importantly, the majority of these patients were on im-
munosuppressant therapy. Immunocompromised states, such 
as HIV infection, malignancy, diabetes, chronic corticosteroid 
use and the use of TNF-α antagonists, are well-known risk fac-
tors for TB and NTMLD (33-38). The occurrence of TB in pa-
tients on immunosuppressant therapy was two times higher 
(2.6%) than that of those on symptomatic therapy (1.3%). Dur-
ing the follow-up period, 13 (81%) of 16 patients with TB and 3 
(60%) of 5 patients with NTMLD had been treated with azathio-
prine or prednisone. The intervals between newly diagnosed 
TB and NTMLD after initiation of immunosuppressant therapy 
were 5.8 ± 2.6 and 8.3 ± 0.2 months, respectively. Considering 
the relatively short duration of immunosuppressant therapy 
before the development of TB or NTMLD, immunosuppres-
sants may be a causal factor in the development of mycobacte-
rial lung disease in these subjects. 
 It is generally recommended that patients on immune sup-
pressants such as prednisone at a dose of over 15 mg per day 
for more than 1 month need a tuberculin test and should con-
sider prophylactic treatment due to their increased susceptibil-
ity to mycobacterial infections (39). In the present study, we did 
not use skin or blood tests to examine latent TB before the start 
of immunosuppressant treatment, because of the high rate of 
BCG immunization in Korea (40). However, the diagnostic value 
of the skin or blood tests for detecting latent tuberculosis infec-
tion and the use of prophylaxis in these cases will be evaluated 
in patients with IPF in the future. 
 Pulmonary TB was cured in about two-thirds of the patients 
but other three patients died of TB progression. About 18% (9 of 
51) of the patients died during treatment with anti-MTB or -NTM 
medications. Their causes of death were similar to typical causes 
in patients with IPF (8). Three patients who had been treated 
with steroids and azathioprine died of TB progression, suggest-
ing the possibility of a rapid fatal course of TB in these patients, 
although the numbers were small. 
 Our study has some limitations. First, due to the retrospective 
design of the study, some IPF cohort patients might not have 
been examined bacteriologically in their sputum or bronchio-
lar lavage fluid during the follow-up period, even when they had 
supporting symptoms or radiological findings. Second, coloni-
zation and disease states in NTMLD were not readily distinguish-
able. Most patients with IPF had respiratory symptoms, such as 
coughing, dyspnea, and fatigue, which also occur in NTMLD. 
Moreover, once organisms were detected, treatment was prompt-
ly initiated without observation in these patients. Thus, in some 
patients, NTMLD may be more unlikely. 
 In summary, we found that the prevalence rates of pulmonary 
TB and NTMLD in a large number of patients with IPF were 4.4% 
and 2.0%, respectively. These rates are significantly higher than 
those in the general population, suggesting the need to more 
carefully test for TB and NTMLD in patients with IPF, not only 
at the initial presentation but also during the follow-up period, 
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